Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neihulizumab for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic cell transplantation was withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Neihulizumab (neihulizumab)

Snippet

Sponsor: AbGenomics B.V Taiwan Branch | Conditions: Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation | Phase 2 | Status: WITHDRAWN